The invention relates to a method of preparation of hyaluronic acid derivative, that has some carboxyl groups (—COOH) replaced by the primary hydroxyl group (—CH2—OH). The method of preparation is based on the carboxyl group activation using 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride agent and subsequent reduction with NaBH4. The hyaluronic acid derivatives prepared according to invention are biocompatible and biodegradable, showing increased resistance to thermal and enzymatic degradation. Formula for annotation (I):
The invention relates to a method of preparation of hyaluronic acid derivative, that has some carboxyl groups (—COOH) replaced by the primary hydroxyl group (—CH2—OH). The method of preparation is based on the carboxyl group activation using 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride agent and subsequent reduction with NaBH4. The hyaluronic acid derivatives prepared according to invention are biocompatible and biodegradable, showing increased resistance to thermal and enzymatic degradation. Formula for annotation (I):
I═R1-(A)X-(B)Y—R2
wherein
A is a structural fragment of a linear chain:
The invention relates to a method of preparation of hyaluronic acid derivative, that has some carboxyl groups (—COOH) replaced by the primary hydroxyl group (—CH2—OH). The method of preparation is based on the carboxyl group activation using 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride agent and subsequent reduction with NaBH4. The hyaluronic acid derivatives prepared according to invention are biocompatible and biodegradable, showing increased resistance to thermal and enzymatic degradation. Formula for annotation (I):
I═R1-(A)X-(B)Y—R2
wherein
A is a structural fragment of a linear chain:
B is a structural fragment of a linear chain:
The invention relates to a method of preparation of hyaluronic acid derivative, that has some carboxyl groups (—COOH) replaced by the primary hydroxyl group (—CH2—OH). The method of preparation is based on the carboxyl group activation using 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride agent and subsequent reduction with NaBH4. The hyaluronic acid derivatives prepared according to invention are biocompatible and biodegradable, showing increased resistance to thermal and enzymatic degradation. Formula for annotation (I):
I═R1-(A)X-(B)Y—R2
wherein
A is a structural fragment of a linear chain:
B is a structural fragment of a linear chain:
R1 is the structural fragment of the end of the linear chain:
The invention relates to a method of preparation of hyaluronic acid derivative, that has some carboxyl groups (—COOH) replaced by the primary hydroxyl group (—CH2—OH). The method of preparation is based on the carboxyl group activation using 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride agent and subsequent reduction with NaBH4. The hyaluronic acid derivatives prepared according to invention are biocompatible and biodegradable, showing increased resistance to thermal and enzymatic degradation. Formula for annotation (I):
I═R1-(A)X-(B)Y—R2
wherein
A is a structural fragment of a linear chain:
B is a structural fragment of a linear chain:
R1 is the structural fragment of the end of the linear chain:
R2 is the structural fragment of the end of the linear chain:
The invention relates to a method of preparation of hyaluronic acid derivative, that has some carboxyl groups (—COOH) replaced by the primary hydroxyl group (—CH2—OH). The method of preparation is based on the carboxyl group activation using 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride agent and subsequent reduction with NaBH4. The hyaluronic acid derivatives prepared according to invention are biocompatible and biodegradable, showing increased resistance to thermal and enzymatic degradation. Formula for annotation (I):
I═R1-(A)X-(B)Y—R2
wherein
A is a structural fragment of a linear chain:
B is a structural fragment of a linear chain:
R1 is the structural fragment of the end of the linear chain:
R2 is the structural fragment of the end of the linear chain:
M can be hydrogen or any alkali metal cation,
X is an index indicating the number of structural fragments A within the chain,
Y is an index indicating the number of structural fragments B within the chain, while at the same time:
structural fragments A and B are randomly distributed in the linear chain, and
the sum of the X+Y indexes is in the range of 500 to 2,500, and
the ratio of the X/Y indexes is in the range of 3/1 to 1/4.
The present invention relates to an ester conjugate of sphingolipid and hyaluronan, a composition comprising thereof and its use. Furthermore, it relates to methods of the ester conjugate synthesis.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
3.
METHOD OF PRODUCTION OF FIBERS AND A DEVICE FOR CARRYING OUT THE METHOD
The present invention relates to a method and device for the production of microfibres or nanofibres based on hyaluronic acid and/or a water-soluble metal or non-metal salt thereof or a mixture of salts and/or a derivative of hyaluronic acid by the method of dry spinning and/or solution blow spinning, and two-dimensional or three-dimensional fibrous materials from said microfibres and nanofibres. The resulting 2D or 3D materials can be for example in the form of a layer or cotton wool. Furthermore, the present invention relates to a device for carrying out the method, that contains an extrusion piece containing a pass-through channel, that has an inlet opening for feeding the spinning solution and a dispensing opening for dispensing the spinning solution and furthermore the device contains an air nozzle, the air outlet opening of which is arranged to direct the exiting air into the area surrounding the dispensing opening of the extrusion piece parallel to the axis of the dispensing opening of the extrusion piece.
The present invention refers to a method and device for the production of microfibres or nanofibres based on hyaluronic acid and/or a water-soluble metal or non-metal salt thereof or a mixture of salts and/or a derivative of hyaluronic acid by method of dry spinning and/or solution blow spinning, and two-dimensional or three-dimensional fibrous materials from this microfibres and nanofibres. The resulting 2D or 3D materials can be for example in the shape of a layer or cotton wool. Furthermore, the present invention relates to a device for carrying out this method, that contains an extrusion piece containing a pass-through channel, that has an inlet opening for feeding the spinning solution and a dispensing opening for dispensing the spinning solution and furthermore the device contains an air nozzle, the air outlet opening of which is arranged to direct the exiting air into the area surrounding the dispensing opening of the extrusion piece parallel to the axis of the dispensing opening of the extrusion piece.
D01D 5/14 - Méthodes de filage par étirage par circulation de fluides provoquant l'étirage
5.
KIT OF GEL-FORMING SOLUTIONS INTENDED FOR PREPARATION OF HYDROGEL BASED ON COVALENTLY CROSSLINKED HYDROXYPHENYL DERIVATIVE OF HYALURONAN FOR PREVENTION OF POSTOPERATIVE COMPLICATIONS RELATED TO FORMATION OF COLORECTAL ANASTOMOSIS, USE OF KIT, METHOD OF PREPARATION OF HYDROGEL AND USE THREREOF
A kit of gel-forming solutions for a preparation of a biodegradable hydrogel based on a covalently crosslinked hydroxyphenyl derivative of hyaluronan is provided. The kit comprises at least two aqueous solutions, A and B, wherein the solution A comprises horseradish peroxidase and the solution B comprises hydrogen peroxide. At least one of the solution A and/or the solution B comprises a hydroxyphenyl derivative of a hyaluronan, and at least one of the solution A and/or the solution B comprises triclosan and hydroxypropyl-β-cyclodextrin. A method of preparing a hydrogel containing a covalently crosslinked hydroxyphenyl derivative of hyaluronan, from the kit, is also provided. The method comprises preparing separately the at least two solutions A and B, and mixing together the solution A with the solution B to form the hydrogel containing a covalently crosslinked hydroxyphenyl derivative of hyaluronan.
Streptococcus pneumoniaeStreptococcus pneumoniae hyaluronate lyase), as well as a selective negative effect on the viability of certain cancer cell lines.
The present invention relates to wound healing means comprising nanofibrous carrier based on two types of hyaluronic acid derivatives, the photocurable derivative of HA and the hydrophobized derivative of HA or the pharmaceutically acceptable salts thereof and which combine to form a mechanically resistant nanofibrous structure that is stable in aqueous solutions. The invention further relates to a method of manufacture of such means and use thereof.
The invention relates to a cryopreservation medium, which is a solution of high molecular hyaluronic acid and DMSO in stem cell culture salts, where high molecular weight hyaluronic acid has the molecular weight higher than 1,000,000 g/mol and concentration in the range from 0.08 to 0.2% (w/v). The cryopreservation medium is designed to preserve cell lines and stem cells under very low temperature conditions and allows a reduction in the concentration of the potentially cytotoxic cryop rotective dimethyl sulfoxide (DMSO). Furthermore, the present invention relates to the use of cryopreservation medium and the method of cryopreservation.
The invention relates to a method of preparation of hyaluronic acid derivative, that has some carboxyl groups (-COOH) replaced by the primary hydroxyl group (-CH2-OH). The method of preparation is based on the carboxyl group activation using 4-(4,6-dimethoxy-l,3,5- triazine-2-yl)-4-methylmorpholinium chloride agent and subsequent reduction withNaBHU. The hyaluronic acid derivatives prepared according to invention are biocompatible and biodegradable, showing increased resistance to thermal and enzymatic degradation. Formula for annotation (I): I = R1- ( A )X - ( B )Y - R2wherein A is a structural fragment of a linear chain: B is a structural fragment of a linear chain: R1is the structural fragment of the end of the linear chain: R2 is the structural fragment of the end of the linear chain:
The present invention refers to a method and device for the preparation of microfibres and nanofibres based on hyaluronic acid and/or a water-soluble metal or non-metal salt thereof or a mixture of salts and/or a derivative of hyaluronic acid by method of dry spinning, and two- dimensional or three-dimensional fibrous materials from this microfibres and nanofibres. The resulting 2D or 3D materials can be for example in the shape of layer or cotton wool. Furthermore, the present invention refers to a device for performing this method, that contains an extrusion part containing a pass-through channel, that has an inlet opening for feeding the spinning solution and a dispensing opening for dispensing the spinning solution and furthermore the device contains an air nozzle, the air outlet opening of which is arranged to direct the exiting air into the area surrounding the dispensing opening of the extrusion part parallel to the axis of the dispensing opening of the extrusion part.
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
D01D 7/00 - Réception des produits nouvellement filés
D01F 9/00 - Filaments, ou similaires, faits par l’homme, formés d’autres substancesLeur fabricationAppareils spécialement adaptés à la fabrication de filaments de carbone
13.
DENTAL PREPARATION COMPRISING FIBERS BASED ON HYALURONIC ACID WITH REGULATED BIODEGRADABILITY
A biodegradable dental preparation comprising at least one water-soluble fiber from hyaluronic acid or a physiologically acceptable salt thereof and at least one fiber from a non-polar derivative of hyaluronic acid is disclosed. The dental preparation may comprise an antimicrobial agent. The dental preparation may be useful in the treatment of periodontal disease or in the treatment of injuries in the periodontium and oral mucosa. Methods of preparing the dental preparations, fibers thereof, and related compositions thereto, are also disclosed.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
Materials and methods for preparing a hydrogel are disclosed. Specifically, two separate solutions A and B, of which the solution A comprises enzyme horseradish peroxidase and the solution B comprises hydrogen peroxide is provided. At least one of solution A or B comprises calcium ions in the form of a pharmaceutically acceptable salt, and further the solution A and/or the solution B comprises hydroxyphenyl derivative of hyaluronan of a particular formula. A hydrogel based on hydroxyphenyl derivative of hyaluronan and a method of preparing and using the same is also disclosed.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Food supplements and dietary preparations for humans, food
supplements and dietary preparations for animals, food
supplements for non-medical purposes, nutritional
supplements for foodstuffs for animals. Foodstuffs and fodder for animals.
16.
WOUND HEALING MEANS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
The present invention relates to wound healing means comprising nanofibrous carrier based on two types of hyaluronic acid derivatives, the photocurable derivative of HA and the hydrophobized derivative of HA or the pharmaceutically acceptable salts thereof and which combine to form a mechanically resistant nanofibrous structure that is stable in aqueous solutions. The invention further relates to a method of manufacture of such means and use thereof.
A61L 15/16 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
17.
KIT OF GEL-FORMING SOLUTIONS INTENDED FOR PREPARATION OF HYDROGEL BASED ON COVALENTLY CROSSLINKED HYDROXYPHENYL DERIVATIVE OF HYALURONAN FOR PREVENTION OF POSTOPERATIVE COMPLICATIONS RELATED TO FORMATION OF COLORECTAL ANASTOMOSIS, USE OF KIT, METHOD OF PREPARATION OF HYDROGEL AND USE THEREOF
The kit of at least two aqueous gel-forming solutions for the preparation of a biodegradable hydrogel based on a covalently crosslinked hydroxyphenyl derivative of hyaluronan, comprising at least two aqueous solutions A and B, of which the solution A contains horseradish peroxidase and the solution B contains hydrogen peroxide, wherein the solution A and/or the solution B comprises a hydroxyphenyl derivative of a hyaluronan of the general formula I, wherein n is in the range 2 to 5000, M is H+2111122 is alkylene of 3 to 7 carbons, and at the same time the solution A and/or B contains triclosan and hydroxypropyl β-cyclodextrin. It further relates to the use of the kit, the method of preparation of the hydrogel and use thereof.
An antimicrobial composition is provided. The composition comprises a chloramid of hyaluronic acid or of modified hyaluronic acid. The chloramid has an amidic group (—NH—CO—). The hydrogens of the amidic group are substituted by chlorine atoms according to the structural formula —NCl—CO—. The composition further comprises an iodide. The substitution degree of the hyaluronic acid or of the modified hyaluronic acid by chlorine is in an amount of from 50% to 100%.
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
A01N 25/08 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des solides comme supports ou diluants
A chlorinated derivative of hyaluronic acid or of a modified hyaluronic acid (chloramide) is provided. The chloramide has an amidic group (—NH—CO—). The hydrogen of the amidic group is substituted by a chlorine atom, according to the structural formula —NCl—CO—. The substitution degree of the hyaluronic acid or of the modified hyaluronic acid by chlorine is in an amount of from 50 to 100 %.
Device for the production of nanofibrous and/or microfibrous layers having an increased thickness uniformity by spinning a liquid material (3), said device comprising: a collecting electrode (6), a spinning nozzle (1) for dispensing the liquid material (3) to be spun, an assembly for guiding the collecting electrode (6) and/or for guiding a base strip (5) along the collecting electrode (6) or adjacent to it, such that—in the area faced by the outlet orifice (10) of the spinning nozzle (1)—the collecting electrode (6) and/or the base strip (5) move(s) in the direction (MD) spaced from the outlet orifice (10) of the spinning nozzle (1), a power supply for generating a voltage of 10 to 150 kV between the collecting electrode (6) and the spinning nozzle (1), at least one body (2), which moves along the liquid surface to destabilize the locations of the points where fibres (4) are formed on the surface of the liquid material (3) at the outlet orifice (10) of the spinning nozzle (1). The nanofibrous and/or microfibrous layers having an increased thickness uniformity are produced by spinning a liquid material (3) in an electrostatic field, wherein a body (2) is moved along the surface of the spun liquid in order to destabilize positions of locations, where the fibers originate.
The invention concerns casein-derived pentapeptide as an enhancer of skin cells having a general formula I wherein: X is –NHX1group of asparagine at the N-terminal end of the peptapeptide is, wherein X1is selected from a group comprising H, acetyl, octanoyl, decanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, elaidoyl, oleoyl, biotinoyl or lipoyl; Z is –COZ1group of glutamine at the C-terminal end of the peptapeptide, wherein Z132322; and a topical composition comprising thereof and topical use thereof.
A61K 8/92 - Huiles, graisses ou ciresLeurs dérivés, p. ex. produits d'hydrogénation
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
22.
DENTAL PREPARATION COMPRISING FIBERS BASED ON HYALURONIC ACID WITH REGULATED BIODEGRADABILITY
The present invention relates to a biodegradable dental preparation comprising at least one water-soluble fiber from hyaluronic acid or a physiologically acceptable salt thereof and at least one fiber from a non-polar derivative of hyaluronic acid. In a preferred embodiment, the dental composition comprises an antimicrobial agent. The dental preparation is intended for use, in particular, in the treatment of periodontal disease or in the treatment of injuries in the periodontium and oral mucosa.
Hydrogel based on a crosslinked hydroxyphenyl derivative of hyaluronic acid containing molecules of a hydroxyphenyl derivative of hyaluronic acid (HA-TA) or its pharmaceutically acceptable salt of a general formula (I) where n is in the range 2-7500 and where R1is H+or ion of alkali salt or salt of alkali earth metal and R2is OH or tyramine substituent of general formula (II): whereas within one molecule of the hydroxyphenyl derivative of hyaluronic acid or its pharmaceutically acceptable salt of the general formula (I) is at least one R2 tyramine substituent of the general formula (II) and whereas at least two tyramine substituents of the general formula (II) are connected through covalent bond in any ortho position of phenyl groups, and it further contains chondroitin sulfate or its pharmaceutically acceptable salt selected from the group comprising alkali salt or salt or alkali earth metal.
C08L 101/14 - Compositions contenant des composés macromoléculaires non spécifiés caractérisées par des propriétés physiques, p. ex. anisotropie, viscosité ou conductivité électrique les composés macromoléculaires étant solubles dans l'eau ou gonflables dans l'eau, p. ex. gels aqueux
25.
MEANS FOR USE IN PREPARATION OF HYDROGEL BASED ON HYDROXYPHENYL DERIVATIVE OF HYALURONAN, METHOD OF HYDROGEL PREPARATION AND USE THEREOF
2111122 is alkylene of number of carbon atoms 3 to 7. The present invention further relates to the hydrogel based on hydroxyphenyl derivative of hyaluronan and the method of preparation and use thereof.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
26.
MICROPARTICLES BASED ON ESTER DERIVATIVES OF HYALURONAN, METHOD OF PRODUCTION, COMPOSITION COMPRISING THEREOF AND USE THEREOF
Microparticles based on ester derivatives of hyaluronan comprising a conjugate of all-trans retinoic acid and hyaluronan of the general formula I, wherein n is integer in the range of 1 to 5000 dimers, R4is H+or a pharmaceutically acceptable salt, R3is -H or all-trans retinoic acid residue of the formula II, where X is in the place of covalent bond of all-trans retinoic acid residue of the formula II, providing that at least one R3 of the conjugate is all-trans retinoic acid residue of the formula II and wherein the degree of substitution of all-trans retinoic acid residue of the formula II in the conjugate of hyaluronan is in the range from 0.1 to 8 %.
A kit, which contains a biologically active preparation (3) having the form of a slice or a leaf, said kit further containing an underlying foil (1), which comprises at least one cavity (2), and a covering foil (4), the latter being attached to the underlying foil (1), thereby enclosing the cavity (2) making the same impervious to air and/or to water, at least one slice or leaf of the biologically active preparation (3) being accommodated within the cavity (2).
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A45D 37/00 - Sachets spécialement conçus pour les produits de toilette ou cosmétiques liquides
B65D 75/36 - Objets ou matériaux enveloppés entre deux feuilles ou flans opposés à bords réunis, p. ex. par adhésifs à pression, pliage, thermosoudage ou soudage une ou les deux feuilles ou flans étant renfoncés pour épouser la forme du contenu une feuille ou un flan étant renfoncés et l'autre fait d'une feuille plate relativement rigide, p. ex. empaquetage pour ampoules
30.
CHLORINATED DERIVATIVE OF HYALURONIC ACID, METHOD OF PREPARATION THEREOF, A COMPOSITION CONTAINING THE DERIVATIVE, AND USE THEREOF
The invention relates to the preparation and use of various forms comprising a derivative of hyaluronic acid - a hyaluronan chloramide, in which most of the hydrogen atoms of the amidic group -NH-CO- are replaced by chlorine atoms -NCI-CO-. The compositions comprising the hayluronan chloramide exhibit a broad-range antimicrobial and antivirus activity, and thanks to its biocompatibility they are suitable for applications in the field of wound covers or for preparation of a broad range of implantable medical devices.
The invention relates to the preparation and use of various forms comprising iodides and a derivative of hyaluronic acid - a hyaluronan chloramide. These compositions, after being mixed in an aqueous medium, release compounds of iodine in the oxidation degree higher than -1, thus exhibiting a broad-spectrum antimicrobial activity. Thanks to the biocompatibility and stability these compositions are suitable for applications in the field of wound covers or for the preparation of wide range of implantable medical devices.
Device for the production of nanofibrous and/or microfibrous layers having an increased thickness uniformity by spinning a liquid material (3), said device comprising: a collecting electrode (6), a spinning nozzle (1) for dispensing the liquid material (3) to be spun, an assembly for guiding the collecting electrode (6) and/or for guiding a base strip (5) along the collecting electrode (6) or adjacent to it, such that - in the area faced by the outlet orifice (10) of the spinning nozzle (1) - the collecting electrode (6) and/or the base strip (5) move(s) in the direction (MD) spaced from the outlet orifice (10) of the spinning nozzle (1), a power supply for generating a voltage of 10 to 150 kV between the collecting electrode (6) and the spinning nozzle (1), at least one body (2), which moves along the liquid surface to destabilize the locations of the points where fibres (4) are formed on the surface of the liquid material (3) at the outlet orifice (10) of the spinning nozzle (1). The nanofibrous and/or microfibrous layers having an increased thickness uniformity are produced by spinning a liquid material (3) in an electrostatic field, wherein a body (2) is moved along the surface of the spun liquid in order to destabilize positions of locations, where the fibers originate.
D01D 5/00 - Formation des filaments, fils ou similaires
D04H 1/728 - Non-tissés formés uniquement ou principalement de fibres coupées ou autres fibres similaires relativement courtes caractérisés par la méthode de formation des voiles ou couches, p. ex. par la réorientation des fibres les fibres étant disposées au hasard par électrofilage
The present invention relates to solid forms with an antimicrobial activity comprising a polysaccharide and triiodide, where the triiodide decomposition to iodide and volatile iodine is significantly suppressed by the presence of a stabilizer, further it relates to the preparation and use thereof. Compared to the liquid forms comprising triiodide, the stabilized solid forms can be used for a much wider range of applications due to their shape stability and a significantly smaller volume (weight) of total material. Formula for abstract polysaccharide wherein the polysaccharide comprises hyaluronic acid or a chemically modified derivative thereof, sodium alginate, oxycellulose, carboxymethyl cellulose or hydroxyethyl cellulose, R is an alkyl, aromatic, heteroaromatic, linear or branched chain C1 - C30, optionally containing N or O atoms, R1 is an alkyl, aromatic, heteroaromatic, linear or branched chain C1 - C30, optionally containing N or O atoms, or -H, where R1 in the stabilizer are independently the same or different.
A01N 25/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des ingrédients stabilisant les ingrédients actifs
A01N 59/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des éléments ou des composés inorganiques
C07D 239/04 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 277/02 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
The invention relates to a method of determination of hyaluronic acid in complex samples by cleavage with SpnHyl enzyme followed by the reaction with 3-methyl-2-benzothiazolinone hydrazone (MBTH) to form a coloured product analysed by spectrophotometry. In case of a high content of glycosaminoglycans, these can be separated by precipitation before the cleavage, e.g. with the use of cetyltrimethylammomumbromide (CTAB) in acetate buffer and salt medium. In case of a high content of reducing sugars, e.g. glucose, their influence can be eliminated, after removing the glycosaminoglycans and before the cleavage, by precipitating hyaluronic acid from the formed supernatant and then redissolving this sediment in acetate buffer and performing the cleavage step.
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C12Q 1/527 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une lyase
40.
Method of crosslinking of polysaccharides using photoremovable protecting groups
2) with the aldehyde group (—CHO) forming a bond of imine type (—N═CH—). Both processes proceed simultaneously and they can be performed under physiological conditions. The advantage of the suggested solution is the temporal and spatial control of crosslinking that allows the preparation of advanced materials for tissue engineering where the crosslink density and thus the mechanical properties in the material structure can be tailored.
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C08B 15/00 - Préparation d'autres dérivés cellulosiques ou de cellulose modifiée
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The present invention describes the ophthalmologic preparation especially for treatment and prevention of ophthalmologic diseases and disorders. This ophthalmologic preparation is in the form of the solid fibrous carrier that comprises water soluble fibers containing hyaluronic acid or its pharmaceutically acceptable salt and/or derivative thereof and further it contains the water soluble synthetic polymer and the active agent, the solid fibrous carrier dissolving at its contact with the eye.
The invention relates to a medical preparation with a carrier based on hyaluronan and its derivatives which is characterized in that it comprises a conjugate of hyaluronic acid and/or its derivative with a medical substance, according to the general formula A-S-N (X), where A is the medical substance S is the way of linking the medical substance with the carrier N is the carrier based on hyaluronic acid and/or its derivatives m is 10 to 1250, n is 100 to 12500, as well as to the production and use thereof. The new medical preparation can be used in the field of medicine and cosmetics.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
43.
Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
C08G 81/00 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p. ex. polymères séquencés
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C08J 3/02 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension
C08J 3/09 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension dans des liquides organiques
The invention relates to the preparation of new polysaccharide derivatives comprising a double bond in the positions 4 and 5 of the pyranose cycle. The method of preparation consists in the oxidation of OH group in the position 6 to an aldehyde, followed by the elimination to form a double -C=C- bond in the positions 4 and 5, and the final reduction of the aldehyde group in the position 6 into the original alcohol. The derivatives of polysaccharides prepared according to the invention show an enhanced antioxidant activity and some of them also a selective negative influence on carcinoma cell viability. (formula) where R represents -NH-CO-CH3 or -OH.
The present invention relates to the fluorescent conjugate of hyaluronic acid containing cypate or salts thereof, the hydrophobized conjugate, methods of the preparation and use thereof in medicinal applications for in vivo imaging and the treatment of neoplasms.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
ENDLESS CORE-SHEATH FIBERS ON THE BASIS OF HYALURONAN OR C11-C18 ACYLATED DERIVATIVES THEREOF, METHOD OF PREPARATION AND USE THEREOF, STAPLE FIBERS, YARN AND TEXTILES MADE OF THESE FIBERS AND USE THEREOF
The invention relates to two-component biodegradable core-sheath fibers comprising a combination of native and C11-C18 acylated hyaluronan or C11-C18 acylated hyaluronans. It further relates to method of preparation and use thereof, especially for controlled release of the active agent. Fibers may be further processed into the form of staple fibers, yarn, braided, woven, knitted and non-woven textiles.
The invention relates to conjugates of hyaluronic acid oligomer according to the general formulae I, II III or IV, or a salt thereof, the method of preparation thereof and use thereof, where the oligomer is bonded to the respective substrate by its ending anomeric center via a bi-functional amino linker by means of an amino or imino bond. This type of conjugates allows releasing oligomers in their native form. The prepared systems exhibited an enhanced biological activity against selected lines of cancer cells.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
49.
DERIVATIVES OF SULFATED POLYSACCHARIDES, METHOD OF PREPARATION, MODIFICATION AND USE THEREOF
The invention relates to the preparation and the use of α,β-unsaturated aldehydes in the structure of sulfated polysaccharides. It concerns the derivatives with a conjugated double bond in the 4th and 5th positions of the galactopyranose part situated in the 6th position with respect to the aldehyde, according to the general structural formula (I) or its hydrated form according to the general structural formula (II). The preparation of these derivatives derives from sulfated polysaccharides containing a galactopyranose ring sulfated in the 4th position that is bound in the polymer chain via α(1→3) or β(1→3) O-glycosidic bond. In the described solution, the sulfated polysaccharides undergo a regio- and chemoselective oxidation to form C6-saturated aldehyde, which, via a direct elimination of the sulfate group, provides the α,β- unsaturated derivative according to the general formula (I) or (II). The described solution is technically advantageous, because it leads directly to α,β-unsaturated aldehydes, without any elimination agents, higher temperature, or isolation of intermediates during the synthesis. The conjugation in the structure of α,β-unsaturated aldehyde allows, under physiological conditions, to bind a wide variety of biocompatible amines in the structure of the sulfated polysaccharides. The proposed method allows to prepare materials suitable for pH-responsive drug delivery systems, or for the preparation of scaffolds in tissue engineering or regenerative medicine. Formulae for the abstract (I), (II) above, where R is OH, O-SO2-OH, O-SO2-ONa, or NH-Ac.
The present invention relates to pharmaceutical compositions for the treatment or prevention of ophthalmologic diseases or disorders, wherein the pharmaceutical composition comprises a solid carrier in form of a non-woven or woven made of water-soluble fibers and at least one therapeutically active agent, wherein said solid carrier is impregnated with said at least one therapeutically active agent, wherein the solid carrier readily disintegrates upon contact with the eye. Also encompassed are such composition for use in the treatment or prevention of ophthalmologic conditions and the use of the non-wovens/wovens described herein as carriers for at least one therapeutically active agent in an ophthalmologic pharmaceutical composition.
The invention discloses a method of preparation of crosslinked materials based on polysaccharides using electromagnetic radiation in an aqueous solution containing a polysaccharide with a bound carbamate photoremovable protecting group (PPG with group - NH-CO-O-) and a polysaccharide containing an aldehyde group -CHO. The crosslinking process itself is carried out by means of a condensation reaction of the photochemically released amino group (-NH2) with the aldehyde group (-CHO) forming a bond of imine type (-N=CH-). Both processes proceed simultaneously and they can be performed under physiological conditions. The advantage of the suggested solution is the temporal and spatial control of crosslinking that allows the preparation of advanced materials for tissue engineering where the crosslink density and thus the mechanical properties in the material structure can be tailored.
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C08B 15/00 - Préparation d'autres dérivés cellulosiques ou de cellulose modifiée
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
52.
SELF-SUPPORTING, BIODEGRADABLE FILM BASED ON HYDROPHOBIZED HYALURONIC ACID, METHOD OF PREPARATION AND USE THEREOF
The invention relates to a self-supporting, biodegradable film comprising a C10-C22-acylated derivative of hyaluronic acid according to the general formula (I), where R is H+ or Na+, and where R1 is H or -C(=O)CxHy, where x is an integer within the range from 9 to 21 and y is an integer within the range from 11 to 43 and CxHy is a linear or branched, saturated or unsaturated C9-C21 chain, wherein in at least one repeating unit one or more of R1 is -C(=O)CxHy and where n is within the range from 12 to 4000; a method of preparation thereof and use thereof.
C08J 3/02 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dental plugs for packing wounds, the hydration thereof, and mechanical protection following tooth extraction, in particular dental plugs containing sodium hyaluronate and octenidine.
54.
18-acylated derivative of hyaluronic acid and method of preparation thereof
The invention relates to a method of preparation hydrophobized hyaluronic acid (Formula I) and further to a method of encapsulating biologically active substances into the nanomicelles of hydrophobized hyaluronan serving as carriers of biologically active hydrophobic substances. The hydrophobization of hyaluronan is carried out through an esterification reaction of hyaluronan with long-chain carboxylic acids, the latter being activated by a halogenide derivative of 2,4,6-trichlorobenzoic acid or by another organic chloride. In an aqueous environment, water-soluble hydrophobized derivatives can form nanomicelles in which nonpolar substances can be bound by means of non-covalent physical interactions. The core of a nanomicelle is formed by hydrophobic acyl functional groups while the shell of a nanomicelle is formed by hyaluronic acid. The encapsulation of the substances into nanomicelles can be performed by means of the solvent exchange method or by means of sonication. Hyaluronic nanomicelles support the penetration of bound substances in topical applications and enable the bound substances to be transferred into the individual cells. The nanomicelles obtained from hydrophobized hyaluronan derivatives are usable in cosmetic and pharmaceutical applications.
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
C08K 3/30 - Composés contenant du soufre, du sélénium ou du tellure
A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
55.
Hyaluronic acid derivative, method of preparation thereof, method of modification thereof and use thereof
The invention relates to the preparation and use of α,β-unsaturated aldehyde of hyaluronan having a double bond in the positions 4 and 5 and an aldehydic group in the position 6 of the glucosamine part of the polysaccharide. The method of preparation is based on dehydration of hyaluronan having an aldehydic group in the position 6 of the glucosamine part of the polysaccharide. Two methods have been described, which are dehydration in a solution or heating in solid state in absence of solvents, bases or other additives. This derivative allows stabilization of conjugates of hyaluronan with amino compounds by means of a multiple bond from the aldehyde side, and therefore, it is possible to effectively immobilize practically any compound containing an amino group to such modified hyaluronan in physiological conditions. In case of using a diamine or compounds or polymers containing three or more amino groups, it is possible to prepare crosslinked hyaluronan derivatives. The described solution brings along a significant advantage not only in the field of carriers of biologically active substances, but also in tissue engineering where crosslinking with biologically acceptable amino compounds in physiological conditions is very much demanded.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
C07K 17/10 - Peptides immobilisés sur, ou dans, un support organique le support étant un hydrate de carbone
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
The invention related to hyaluronic derivative according to formula (I), methods of preparation thereof and a hydrogel prepared obtained from the derivative and methods of preparation thereof. The hydrogel can be used in tissue engineering, cosmetics, medicine or regenerative medicine such as the forming of scaffolds for the treatment of articular cartilage or bone tissue defects.
{hacek Over (r)}ebí{hacek Over (c)}ek, Ji{hacek Over (r)}i
Velebný, Vladimír
Abrégé
The combined spinning nozzle for the production of nanofibrous or microfibrous materials comprises a thin-walled electrode (1) and a first non-conductive body (2) adjoining the first wall of said thin-walled electrode, said first body having its wall, which faces the thin-walled electrode (1), provided with an array of grooves (5) formed therein, said grooves leading to the distal end (6) of the combined spinning nozzle and having their proximal ends connected to a supply of spinning mixture. The thin-walled electrode (1) and the first non-conductive body (2) may assume either plate-like or cylindrical shapes. The combined spinning nozzle may further comprise a second non-conductive body (4) adjoining a second wall of the thin-walled electrode (1) and directing the air from the proximal end towards the distal end (6) of the nozzle.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemical substances for the manufacture of cosmetics; Chemical substances for the manufacture of medicines except unprocessed artificial resins and unprocessed plastics.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals for the cosmetic, pharmaceutical or food industries, namely, chemical additives for use in the manufacture of food, pharmaceuticals or cosmetics
An apparatus for a production of two-dimensional or three-dimensional fibrous materials of microfibers or nanofibers containing a set of spinning metal nozzles connected to a first potential, a set of electrodes of a collector facing the set of the nozzles, arranged at regular spacing and connected to a second potential, and a collecting plate or a collecting cylinder for collecting microfibers or nanofibers settled between couples of adjacent electrodes of the collector. The substance of the invention is as follows: the set of the electrodes of the collector contains at least two electrodes of the collector arranged in a plane and the collecting plate in line of its intersection or a tangent to the collecting cylinder, that is perpendicular to a contact line with the plane of the electrodes of the collector, form with the plane of the electrodes of the collector an angle α, the size of which ranging between 0° and 90°, the collecting plate or the collecting cylinder being supported movably in relation to the electrodes of the collector in a direction lying in the plane that is perpendicular to the plane of the electrodes of the collector and in which the axis of the electrode lies, the direction of the collecting plate or the collecting cylinder movement forming with this electrode axis an angle β, the size of which ranging between 0° and 90°. Such arrangement enables creating of large areal and voluminous objects of ordered nanofibers.
